Towards more accurate pharmacophore modeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2

Journal of Molecular Graphics and Modelling

Volumn 27, Issue 4, 2008, Pages 430-438

  Zou, Jun ^a   Xie, Huan Zhang ^a   Yang, Sheng Yong ^a   Chen, Jin Juan ^a   Ren, Ji Xia ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

CDK2 inhibitors; Pharmacophore; Protein kinase; Structure based method; Virtual screening

Indexed keywords

COMPLEXATION; LEAD COMPOUNDS; LIGANDS; MAPS; MODEL STRUCTURES;

CDK2 INHIBITORS; PHARMACOPHORE; PROTEIN KINASE; STRUCTURE-BASED METHOD; VIRTUAL SCREENING;

PHARMACODYNAMICS;

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEIVER OPERATING CHARACTERISTIC;

CYCLIN-DEPENDENT KINASE 2; LIGANDS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY;

EID: 56149110450     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2008.07.004     Document Type: Article

References (39)

1. Wermuth C.G. Pharmacophores: historical perspective and viewpoint from a medicinal chemist. In: Langer T., and Hoffmann R.D. (Eds). Pharmacophores and Pharmacophore Searches (2006), Wiley-VCH 3-13
2. Ekins S., Mestres J., and Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br. J. Pharmacol. 152 (2007) 9-20
3. Ekins S., Mestres J., and Testa B. In silico pharmacology for drug discovery: applications to targets and beyond. Br. J. Pharmacol. 152 (2007) 21-37
4. Poptodorov K., Luu T., and Hoffmann R.D. Pharmacophore model generation software tools. In: Langer T., and Hoffmann R.D. (Eds). Pharmacophores and Pharmacophore Searches (2006), Wiley-VCH 17-47
5. Dror O., Shulman-Peleg A., Nussinov R., and Wolfson H.J. Predicting molecular interactions in silico. I. A guide to pharmacophore identification and its applications to drug design. Curr. Med. Chem. 11 (2004) 71-90
6. Khedkar S.A., Malde A.K., Coutinho E.C., and Srivastava S. Pharmacophore modeling in drug discovery and development: an overview. Med. Chem. 3 (2007) 187-197
7. Wolber G., Seidel T., Bendix F., and Langer T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov. Today 13 (2008) 23-29
8. Kurogi Y., and Güner O.F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem. 8 (2001) 1035-1055
9. Güner O.F. History and evolution of the pharmacophore concept in computer-aided drug design. Curr. Topics Med. Chem. 2 (2002) 1321-1332
10. Xiao Z., Varma S., Xiao Y.-D., and Tropsha A. Modeling of p38 mitogen-activated protein kinase inhibitors using the Catalyst HypoGen and k-nearest neighbor QSAR methods. J. Mol. Graphics Modell. 23 (2004) 129-138
11. Kirchmair J., Laggner C., Wolber G., and Langer T. Comparative analysis of protein-bound ligand conformations with respect to catalyst's conformational space subsampling algorithms. J. Chem. Inf. Model. 45 (2005) 422-430
12. Kirchmair J., Wolber G., Laggner C., and Langer T. Comparative performance assessment of the conformational model generators omega and catalyst: a large-scale survey on the retrieval of protein-bound ligand conformations. J. Chem. Inf. Model. 46 (2006) 1848-1861
13. Kirchmair J., Ristic S., Eder K., Markt P., Wolber G., Laggner C., and Langer T. Fast and efficient in silico 3D screening: toward maximum computational efficiency of pharmacophore-based and shape-based approaches. J. Chem. Inf. Model. 47 (2007) 2182-2196
14. Kristam R., Gillet V.J., Lewis R.A., and Thorner D. Comparison of conformational analysis techniques to generate pharmacophore hypotheses using catalyst. J. Chem. Inf. Model. 45 (2005) 461-476
15. Hecker E.A., Duraiswami C., Andrea T.A., and Diller D.J. Use of catalyst pharmacophore models for screening of large combinatorial libraries. J. Chem. Inf. Comput. Sci. 42 (2002) 1204-1211
16. Toba S., Srinivasan J., Maynard A.J., and Sutter J. Using pharmacophore models to gain insight into structural binding and virtual screening: an application study with CDK2 and human DHFR. J. Chem. Inf. Model. 46 (2006) 728-735
17. Vadivelan S., Sinha B.N., Irudayam S.J., and Jagarlapudi S.A.R.P. Virtual screening studies to design potent CDK2-cyclin A inhibitors. J. Chem. Inf. Model. 47 (2007) 1526-1535
18. Senderowicz A.M. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19 (2000) 6600-6606
19. Sielecki T.M., Boylan J.F., Benfield P.A., and Trainor G.L. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. 43 (2000) 1-18
20. Fischer P.M., and Lane D.P. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. 7 (2000) 1213-1245
21. Toogood P.L. Cyclin-dependent kinase inhibitors fortreating cancer. Med. Res. Rev. 21 (2001) 487-498
22. Huwe A., Mazitschek R., and Giannis A. Small molecules as inhibitors of cyclin-dependent kinases. Angew. Chem., Int. Ed. 42 (2003) 2122-2138
23. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The protein data bank. Nucl. Acids Res. 28 (2000) 235-242
24. Ladbury J.E. Just add water! The effect of water on the specificity of protein-ligand binding sites and its potential application to drug design. Chem. Biol. 3 (1996) 973-980
25. Marti-Renom M.A., Stuart A.C., Fiser A., Sanchez R., Melo F., and Sali A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29 (2000) 291-325
26. Konagurthu A.S., Whisstock J.C., Stuckey P.J., and Lesk A.M. MUSTANG: a multiple structural alignment algorithm. Proteins 64 (2006) 559-574
27. Discovery Studio, Version 1.7 (2006), Accelrys, Inc., San Diego, CA
28. Wolber G., and Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 45 (2005) 160-169
29. Catalyst, Version 4.11 (2005), Accelrys, Inc., San Diego, CA
30. Bradley E.K., Miller J.L., Saiah E., and Grootenhuis P.D.J. Informative library design as an efficient strategy to identify and optimize leads: application to cyclin-dependent kinase 2 antagonists. J. Med. Chem. 46 (2003) 4360-4364
31. Nugiel D.A., Etzkorn A.-M., Vidwans A., Benfield P.A., Boisclair M., Burton C.R., Cox S., Czerniak P.M., Doleniak D., and Seitz S.P. Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors. J. Med. Chem. 44 (2001) 1334-1336
32. Lin R., Connolly P.J., Huang S., Wetter S.K., Lu Y., Murray W.V., Emanuel S.L., Gruninger R.H., Fuentes-Pesquera A.R., Rugg C.A., Middleton S.A., and Jolliffe L.K. 1-acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J. Med. Chem. 48 (2005) 4208-4211
33. Chu X.-J., DePinto W., Bartkovitz D., So S.-S., Vu B.T., Packman K., Lukacs C., Ding Q., Jiang N., Wang K., Goelzer P., Yin X., Smith M.A., Higgins B.X., Chen Y., Xiang Q., Moliterni J., Kaplan G., Graves B., Lovey A., and Fotouhi N. Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-dif luoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. J. Med. Chem. 49 (2006) 6549-6560
34. MDDR Drug Data Report (2007), MDL Information Systems, Inc., San Leandro, CA
35. Verdonk M.L., Berdini V., Hartshorn M.J., Mooij W.T.M., Murray C.W., Taylor R.D., and Watson P. Virtual screening using protein-ligand docking: avoiding artificial enrichment. J. Chem. Inf. Comput. Sci. 44 (2004) 793-806
36. SciTegic Pipeline Pilot, version 6.1.5 (2007), Accelrys, Inc., San Diego, CA
37. Smellie A., Teig S.L., and Towbin P. Poling: promoting conformational variation. J. Comput. Chem. 16 (1995) 171-187
38. Triballeau N., Acher F., Brabet I., Pin J.-P., and Bertrand H.-O. Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J. Med. Chem. 48 (2005) 2534-2547
39. Gopalakrishnan B., Aparna V., Jeevan J., Ravi M., and Desiraju G.R. A virtual screening approach for thymidine monophosphate kinase inhibitors as antitubercular agents based on docking and pharmacophore models. J. Chem. Inf. Model. 45 (2005) 1101-1108